Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia-Reference-Cited by-同舟云学术

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia

Published:2016-04-01 Issue:3 Volume:54 Page:588-601
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Ferri Nicola,Ruscica Massimiliano

Funder

Fondazione Cariplo

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s12020-016-0939-0.pdf

Reference115 articles.

1. S.M. Grundy, Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28(4), 629–636 (2008). doi: 10.1161/ATVBAHA.107.151092

2. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009). doi: 10.1161/CIRCULATIONAHA.109.192644

3. Cholesterol Treatment Trialists, P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, C. Baigent, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008). doi: 10.1016/S0140-6736(08)60104-X

4. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, European Society of Cardiology, European Atherosclerosis Society, ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1), 3–46 (2011)

5. R. Scott, R. O’Brien, G. Fulcher, C. Pardy, M. D’Emden, D. Tse, M.R. Taskinen, C. Ehnholm, A. Keech, I. Fenofibrate, Event lowering in diabetes study. I: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32(3), 493–498 (2009). doi: 10.2337/dc08-1543

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Dietary Approaches to Stop Hypertension (DASH) on Patients with Metabolic Syndrome and Its Potential Mechanisms;Diabetes, Metabolic Syndrome and Obesity;2024-08

2. Metabolic Changes Induced by Bariatric Surgery May be Mediated by PAI-1 and PCSK9 Crosstalk;Archives of Medical Research;2024-07

3. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes;Cardiovascular Drugs and Therapy;2024-06-22

4. Gene Silencing of Angiopoietin-like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line;International Journal of Molecular Sciences;2024-03-26

5. Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications;Canadian Journal of Physiology and Pharmacology;2024-01-01